Business
New Project with Orchard Therapeutics
New Project with Orchard Therapeutics.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology\n \n \n \n \n Oxford, UK - 26 July 2022: \n \n Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Company\"), a leading gene and cell therapy group, today announces that\n it has initiated a new project with Orchard Therapeutics utilising the Company's proprietary LentiStable™ technology.\n \n \n As part of the project,\n Oxford Biomedica's LentiStable™ technology platform will be used to develop a producer cell line capable of stably expressing lentiviral vectors. Using this technology, the project will be focused on developing high-performing candidate clones for Orchard Therapeutics' OTL-203, an investigational\n hemopoietic stem cell\n (HSC) gene therapy in development for the potential treatment of mucopolysaccharidosis type I Hurler's syndrome (MPS-IH).\n As part of an existing collaboration, established in\n \n November 2016\n \n , Orchard Therapeutics\n will explore the technology to increase the manufacturing efficiency and scalability of HSC gene therapy.\n \n \n Oxford Biomedica's cutting edge LentiStable™ technology platform, which is the result of more than 10 years of optimisation work, allows the development of a mammalian cell line which can use a chemical inducer to generate viral vector production without the need for transient transfection. This technology has the potential to deliver highly efficient producer cell lines to enable streamlined, scalable and cost-effective manufacturing.\n \n \n \n Dr. Kyriacos Mitrophanous, Chief Scientific Officer of Oxford Biomedica, commented:\n \n \n \n \"We are pleased to enter into a new project with Orchard Therapeutics, a global gene therapy leader. We are committed to innovation and to the ongoing development of our platform, which is key to our goal of widening access to gene therapy by lowering the cost of viral vector manufacturing. Our proprietary LentiStable™\n \n \n technology shows great promise in support of this goal and underlines our overall position as a leader in cell and gene therapy and our ambition to remain at the forefront of this important work for patients globally.\"\n \n \n \n \n Nicoletta Loggia, Ph.D., Chief Technical Officer of Orchard Therapeutics, added:\n \n \n \"This p...